CGEM

Cullinan Therapeutics (CGEM)

About Cullinan Therapeutics (CGEM)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Details

Daily high

$10.14

Daily low

$9.61

Price at open

$10.10

52 Week High

$13.33

52 Week Low

$5.68

Market cap

571.9M

Dividend yield

0.00%

Volume

1.9M

Avg. volume

1.6M

P/E ratio

-2.63

Cullinan Therapeutics News